上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

产品名称：Z-ILE-LEU-ALDEHYDE
产品别名：Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII

生物活性：

Description	Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of γ-secretase and notch[1][2].	
In Vitro	Z-Ile-Leu-aldehyde (ILCHO) significantly downregulates Th17-associated cytokine levels in murine Th17 in vitro polarization assays[1]. Z-Ile-Leu-aldehyde (GSI XII) induces apoptosis of murine MOPC315.BM myeloma cells with high Notch activity[2].	
	RT-PCRsup>[1]	
	Cell Line:	$CD4^+$ T cells from C57BL/6 mice.
	Concentration:	25 μM.
	Incubation Time:	24, 48, 72 hours.
	Result:	t and IL-17 mRNA expression.γDownregulateD ROR
	Cell Viability Assaysup>[2]	
	Cell Line:	MOPC315.BM cells.
	Concentration:	0, 12, 15 μM.
	Incubation Time:	24-48 h hours.
	Result:	Reduced viability and induced apoptosis in MOPC315.BM cells
In Vivo	Z-Ile-Leu-aldehyde (GSI XII, 10 mg/kg, Intraperitoneally either for 14 days) controls myeloma bone disease mainly by targeting Notch in MM cells and possibly in osteoclasts in their microenvironment[2].	
	Animal Model:	MOPC315.BM mouse model[2].
	Dosage:	10 mg/kg.
	Administration:	Intraperitoneally either for 14 days.
	Result:	Reduces myeloma-specific paraprotein levels in the MOPC315.BM model. Diminished osteolytic lesions in the MOPC315.BM mice.

Solvent&Solubility

In Vitro:

DMSO : ≥ 41 mg/mL (113.12 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.7589 mL	13.7946 mL	27.5893 mL
	5 mM	0.5518 mL	2.7589 mL	5.5179 mL
	10 mM	0.2759 mL	1.3795 mL	2.7589 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

References	[1]. Reem Suleiman, et al. The Role Of Notch In Th17 Differentiation. University of Massachusetts Amherst. 9-2013. [2]. Schwarzer R, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014 Jun 13;4:e217.